Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | QBS10072S |
| Synonyms | |
| Therapy Description |
QBS10072S consists of a cytotoxic small molecule compound that can be transported across the blood-brain barrier by the LAT1 transporter, which potentially induces DNA damage and inhibits tumor growth (PMID: 34635566, PMID: 34646647). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| QBS10072S | QBS-10072S|QBS 10072S|QBS 72S|QBS-72S|QBS72S | QBS10072S consists of a cytotoxic small molecule compound that can be transported across the blood-brain barrier by the LAT1 transporter, which potentially induces DNA damage and inhibits tumor growth (PMID: 34635566, PMID: 34646647). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04430842 | Phase I | QBS10072S | Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S | Completed | AUS | 0 |
| NCT02977780 | Phase II | CC-115 Abemaciclib + Temozolomide Temozolomide Neratinib + Temozolomide QBS10072S | INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT) | Recruiting | USA | 0 |
| NCT05305365 | Phase II | QBS10072S | Study Assessing QBS72S For Treating Brain Metastases | Active, not recruiting | USA | 0 |